<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379557</url>
  </required_header>
  <id_info>
    <org_study_id>LESS AF</org_study_id>
    <nct_id>NCT04379557</nct_id>
  </id_info>
  <brief_title>Ablation Index Guided High Power Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation</brief_title>
  <official_title>Ablation Index Guided High Power Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare the ablation time during pulmonary vein isolation of Ablation&#xD;
      Index-guided high power ablation with those with conventional ablation.&#xD;
&#xD;
      Ablation time of conventional group will be used from OPTIMUM study. For secondary outcomes,&#xD;
      acute outcomes of pulmonary vein isolation using two different strategies will be compared.&#xD;
      During 1 year of follow-up in both groups, atrial fibrillation recurrence will be evaluated.&#xD;
      The atrial fibrillation recurrence rate at 1 year after pulmonary vein isolation will be&#xD;
      compared between the two groups. In addition, fluoroscopic time, procedure time, and&#xD;
      complication rates for the high power ablation group will be compared with those with&#xD;
      conventional power.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ablation Index guided high power ablation will be performed in 70 patients with atrial&#xD;
      fibrillation with prospectively and consecutively. A contact force-sensing catheter will be&#xD;
      used. Ablation will be performed with point-by-point technique using Visitag automated&#xD;
      annotation criteria as below;&#xD;
&#xD;
      Ablation Index(AI) target:&#xD;
&#xD;
        -  Anterior/roof : 450 AI&#xD;
&#xD;
        -  Anterior near carina area : 500 AI&#xD;
&#xD;
        -  Posterior/inferior/carina : 350 AI&#xD;
&#xD;
        -  Posterior near carina area : 400 AI&#xD;
&#xD;
        -  Area near esophagus :25W, 15sec or 300 AI (no further ablation if esophageal temperature&#xD;
           increase more than 39°C)&#xD;
&#xD;
        -  Interlesion distance ≤ 4.5mm&#xD;
&#xD;
      VISITAGTM settings&#xD;
&#xD;
        -  2.5mm stability range&#xD;
&#xD;
        -  7 sec stability time&#xD;
&#xD;
        -  FOT 25%, 3g force&#xD;
&#xD;
        -  Tag size 2mm&#xD;
&#xD;
      Ablation parameters are preset as below;&#xD;
&#xD;
        -  RF power range: 40W at anterior/roof, 30W at posterior/inferior, 25W at near esophagus&#xD;
           area (decrease power 5W by operator decision)&#xD;
&#xD;
        -  Target contact force range: 10-20 g&#xD;
&#xD;
        -  Flow rate:&#xD;
&#xD;
        -  8 ml/min for STSF &lt; 30W&#xD;
&#xD;
        -  15 ml/min for STSF ≥ 30W&#xD;
&#xD;
      Acute reconnection will be analysed according to predefined segments.&#xD;
&#xD;
      Subgroup analysis will be performed according to type of AF. Data of patients with paroxysmal&#xD;
      atrial fibrillation and persistent atrial fibrillation will be analysed separately, and&#xD;
      investigate whether this new ablation strategy is effective in both group of patients. To&#xD;
      compare outcomes with OPITMUM phase 2 study, the proportion of patients with paroxysmal and&#xD;
      persistent atrial fibrillation would be 75% and 25%. Therefore, 53 patients with paroxysmal&#xD;
      atrial fibrillation and 17 patients with persistent atrial fibrillation will be enrolled in&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ablation time</measure>
    <time_frame>during procedure</time_frame>
    <description>To compare ablation time of ablation index guided high power ablation for pulmonary vein isolation in patients with atrial fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>residual potential after first pass pulmonary vein encirclement</measure>
    <time_frame>during procedure</time_frame>
    <description>segment which observed residual potential after first pass pulmonary vein encirclement during procedure (based on predefined pulmonary vein segments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute pulmonary vein reconnection</measure>
    <time_frame>1 year</time_frame>
    <description>segment which observed early re-connection during procedure (based on predefined pulmonary vein segments) time frame: during procedure (20-30 minutes after pulmonary vein isolation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any atrial fibrillation/atrial tachycardia recurrence</measure>
    <time_frame>1-year after index procedure</time_frame>
    <description>detected by 12-lead electrocardiogram or 24-hour holter monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time</measure>
    <time_frame>during procedure</time_frame>
    <description>Total ablation time, fluoroscopic time, and procedure time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complication</measure>
    <time_frame>1 year</time_frame>
    <description>Complications associated with procedure.(bleeding, cardiac tamponade, etc.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>High power ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional ablation applying 30-35W strategy for Left atrium anterior segments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias</description>
    <arm_group_label>Conventional ablation</arm_group_label>
    <arm_group_label>High power ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic paroxysmal or persistent AF who failed anti-arrhythmic&#xD;
             agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had previous ablation for AF&#xD;
&#xD;
          -  Patients with left atrial diameter more than 50 mm&#xD;
&#xD;
          -  Inability or unwillingness to receive oral anticoagulation with a vitamin K antagonist&#xD;
             (VKA) or non-VKA (NOAC) agent&#xD;
&#xD;
          -  Known severe left ventricular systolic dysfunction (ejection fraction &lt;35%)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Euekeun Choi, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National university Hostpital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

